Amgen Terminates Advaxis Immunotherapy Collaboration and Other Deal Terminations

By Michelle Liu

Pharma Deals Review: Vol 2018 Issue 12 (Table of Contents)

Published: 29 Dec-2018

DOI: 10.3833/pdr.v2018.i12.2390     ISSN: 1756-7874

Section: Research & Development



In a surprise move, Amgen has decided to conclude its immunotherapy collaboration with Advaxis to develop and commercialise the latter’s Phase I asset, ADXS-NEO, a personalised cancer immunotherapy treatment...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details